Visugromab

Phase 2Monoclonal antibody

Visugromab is one of 19 biologic programs targeting Metastatic Non-squamous Non Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Non-Squamous Non Small Cell Lung CancerRecruiting

Solid Tumor, AdultActive, not recruiting

Metastatic Hepatocellular CarcinomaRecruiting

Metastatic Non-Squamous Non Small Cell Lung CancerPhase 2

Recruiting

Solid Tumor, AdultPreclinical

Active, not recruiting

Metastatic Hepatocellular CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

29 competitors in Solid Tumor, Adult

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

4 2

Avastin

Roche

Phase 1

2 3

Rybrevant

Johnson & Johnson

Phase 1

1 4

Imjudo

AstraZeneca

Phase 1

1 5

Imfinzi

AstraZeneca

Phase 1

1 6

Jakafi

Incyte

Phase 1

1 7

Tagrisso

AstraZeneca

Phase 1

1 8

Alimta

SShawn Eagle

Phase 1

1 9

Bavencio

EMD Serono

Phase 1

1 10

Alimta

EEagle Pharmaceuticals, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalActive, not recruiting

Solid Tumor, Adult

NCT04725474

Q4 2030

PreclinicalRecruiting

Cachexia

NCT07112196

Q1 2031

Phase 2Recruiting

Metastatic Non-Squamous Non Small Cell Lung Cancer

NCT07098988

Q3 2031

Phase 2Recruiting

Metastatic Hepatocellular Carcinoma

NCT07219459

Clinical

Trials by Indication[1]

Metastatic Non-squamous Non Small Cell Lung Cancer2 trials

Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)

Recruiting·CCatalYm GmbH·Phase 2·NCT07246863·131 enrolled

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07098988·107 enrolled

Cachexia1 trial

Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia

Recruiting·CCatalYm GmbH·Preclinical·NCT07112196·518 enrolled

Solid Tumor, Adult1 trial

A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).

Active, not recruiting·CCatalYm GmbH·Preclinical·NCT04725474·199 enrolled

Bladder Cancer1 trial

A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer

Completed·CCatalYm GmbH·Phase 2·NCT06059547·31 enrolled

Metastatic Hepatocellular Carcinoma1 trial

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07219459·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Visugromab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Visugromab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Visugromab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CatalYm GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: CCatalYm GmbH

Visugromab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q4 2030

Q1 2031

Q3 2031

Trials by Indication[1]

Metastatic Non-squamous Non Small Cell Lung Cancer2 trials

Cachexia1 trial

Solid Tumor, Adult1 trial

Bladder Cancer1 trial

Metastatic Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News